379 related articles for article (PubMed ID: 29310470)
1. New therapies target the toxic consequences of cholestatic liver disease.
Jansen PLM
Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):277-285. PubMed ID: 29310470
[TBL] [Abstract][Full Text] [Related]
2. Primary biliary cholangitis: pathogenesis and therapeutic opportunities.
Gulamhusein AF; Hirschfield GM
Nat Rev Gastroenterol Hepatol; 2020 Feb; 17(2):93-110. PubMed ID: 31819247
[TBL] [Abstract][Full Text] [Related]
3. Novel and emerging therapies for cholestatic liver diseases.
Goldstein J; Levy C
Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
[TBL] [Abstract][Full Text] [Related]
4. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.
Beuers U; Trauner M; Jansen P; Poupon R
J Hepatol; 2015 Apr; 62(1 Suppl):S25-37. PubMed ID: 25920087
[TBL] [Abstract][Full Text] [Related]
5. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
7. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
8. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
9. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?
Beuers U; Kullak-Ublick GA; Pusl T; Rauws ER; Rust C
Clin Rev Allergy Immunol; 2009 Feb; 36(1):52-61. PubMed ID: 18751930
[TBL] [Abstract][Full Text] [Related]
10. Drug Therapies for Chronic Cholestatic Liver Diseases.
Wagner M; Fickert P
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
[TBL] [Abstract][Full Text] [Related]
11. Primary biliary cirrhosis and bile acids.
Corpechot C
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
[TBL] [Abstract][Full Text] [Related]
12. Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives.
Barba Bernal R; Ferrigno B; Medina Morales E; Castro CM; Goyes D; Trivedi H; Patwardhan VR; Bonder A
Turk J Gastroenterol; 2023 Feb; 34(2):89-100. PubMed ID: 36843300
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
Trauner M; Halilbasic E; Kazemi-Shirazi L; Kienbacher C; Staufer K; Traussnigg S; Hofer H
Dig Dis; 2014; 32(5):631-6. PubMed ID: 25034298
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
15. Current Treatment Options for Primary Biliary Cholangitis.
Wong KA; Bahar R; Liu CH; Bowlus CL
Clin Liver Dis; 2018 Aug; 22(3):481-500. PubMed ID: 30259848
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs.
Mita S; Suzuki H; Akita H; Hayashi H; Onuki R; Hofmann AF; Sugiyama Y
Drug Metab Dispos; 2006 Sep; 34(9):1575-81. PubMed ID: 16760228
[TBL] [Abstract][Full Text] [Related]
17. Fibrates and cholestasis.
Ghonem NS; Assis DN; Boyer JL
Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
[TBL] [Abstract][Full Text] [Related]
18. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
[TBL] [Abstract][Full Text] [Related]
19. Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.
Halilbasic E; Fuchs C; Hofer H; Paumgartner G; Trauner M
Dig Dis; 2015; 33 Suppl 2():149-63. PubMed ID: 26641242
[TBL] [Abstract][Full Text] [Related]
20. Current and potential treatments for primary biliary cholangitis.
Shah RA; Kowdley KV
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):306-315. PubMed ID: 31806572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
